Related Experiment Videos
Somatuline Autogel: an extended release lanreotide formulation
1University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW.
Hospital Medicine (London, England : 1998)
|April 6, 2002
Summary
Somatuline Autogel effectively controls growth hormone levels, matching the efficacy of Somatuline LA. Its novel formulation ensures consistent drug release for at least 28 days via subcutaneous injection.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Acromegaly and neuroendocrine tumors require consistent growth hormone suppression.
- Intramuscular Somatuline LA is an established treatment option.
Purpose of the Study:
- To evaluate the efficacy and pharmacokinetic profile of Somatuline Autogel.
- To compare Somatuline Autogel with intramuscular Somatuline LA.
Main Methods:
- Pharmacokinetic analysis of Somatuline Autogel.
- Efficacy comparison with Somatuline LA.
Main Results:
- Somatuline Autogel demonstrates effective control of growth hormone levels.
- Efficacy is comparable to intramuscular Somatuline LA.
- First-order kinetics ensure consistent drug release over at least 28 days with reduced burst release.
Conclusions:
- Somatuline Autogel offers an effective alternative for growth hormone control.
- The subcutaneous formulation provides consistent, long-lasting efficacy.